(VIANEWS) – CONTEXTVISION (CONTX.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Health Information Services industry.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CONTEXTVISION (CONTX.OL) | kr8.98 | 3.46% | 61.1% |
| EQUASENS (EQS.PA) | €48.50 | 1.88% | 27.25% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CONTEXTVISION (CONTX.OL)
3.46% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and Rivent 3D, an image enhancement product for 3D ultrasound. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. The company was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.47.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 19.11. Meaning, the purchaser of the share is investing kr19.11 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
More news about CONTEXTVISION.
2. EQUASENS (EQS.PA)
1.88% Forward Dividend Yield and 27.25% Return On Equity
Equasens Société anonyme provides healthcare IT solutions in Europe. It offers id. PATIENT, a business software; id. MOBILITY, a back-office management software; pandaLAB Pro, an instant messaging solution; Id. VENTE, an HAS-certified drug database; Id. COMMANDE, an order management module; dispensing robots; Services Ségur id; id. DOSAGE, a dosage management and printing module; multimeds reconditioning robot; compliance monitoring module; home delivery module; home equipment rental management module; Visiodroits module; and Website connector. The company also provides id. DESK, an informative and interactive dashboard; id. UP!, a real-time monitoring and control application of id management software; id. EASYQ, a queue management solution; Miaterapia; Id. SHOW, an application for managing real-time communications on pharmacy screens; Pharmaweb; TsGatePro; LMO, a dispensary business software; and LGO, a dispensary management software. In addition, it offers DOMILINK HAD software; mobiSOINS mobility tool; MEMORialis, support software for alzheimer's monitoring teams; HOSPILINK, an hospital information system applications; HOSPILINK DPI, a computerized patient file; HOSPILINK LOOKUP Big Data; eNephro solutions; NOVIAcare solutions; KAP&LINK2, a contact chip card reader terminal and NFC reader; eS-KAP-Ad, a connected nomadic tool incorporating software; KAP-INSIDE, a mobile terminal; and TI-KAP allowing access to contact and contactless cards. Further, the company provides AUTHENTICATOR, a patented authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; ExpressVitale; MédiStory, that automates the transfer of invoicing to the healthcare professional's accounting. Additionally, it offers medical telesecretarial services for healthcare professionals, as well as equipment lease financing solutions. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
Earnings Per Share
As for profitability, EQUASENS has a trailing twelve months EPS of €3.05.
PE Ratio
EQUASENS has a trailing twelve months price to earnings ratio of 15.9. Meaning, the purchaser of the share is investing €15.9 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.25%.
Yearly Top and Bottom Value
EQUASENS’s stock is valued at €48.50 at 16:40 EST, way below its 52-week low of €55.00.
Volatility
EQUASENS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.40%, a negative 0.94%, and a positive 2.02%.
EQUASENS’s highest amplitude of average volatility was 3.64% (last week), 2.02% (last month), and 2.02% (last quarter).
Sales Growth
EQUASENS’s sales growth for the current quarter is negative 2.1%.
More news about EQUASENS.
